Clinical trial · Observational
Multiple Myeloma Minimal Residual Disease
Comparison of Three Methods to Evaluate Residual Disease in Multiple Myeloma
NCT02627261CI-TRIAL-00060681MMRDcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Three methods including flow cytometry, next generation sequencing and determination of circulating tumor cells will be performed at different time points in patients with previously undiagnosed multiple myeloma in order to determine the most sensitive method to detect residual disease
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| blood samples and bone marrow aspirates will be collected | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- patients with multiple myeloma
- description
- blood samples and bone marrow aspirates will be collected in patients at different time point
- interventionNames
- Biological: blood samples and bone marrow aspirates will be collected
Primary outcomes (1)
- measure
- Quantification of residual disease
- timeFrame
- Residual disease is assessed up to 18 months after inclusion
- description
- study the sensitivity of the method of quantification of circulating tumor cells compared to 2 others methods of detection
Secondary outcomes (3)
- measure
- kinetic of variation of the residual tumor cells detected by flow cytometry method
- timeFrame
- 18 months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * ≥ 18 years * previously undiagnosed myeloma * eligible for high dose therapy and bone marrow transplantation * signed consent Exclusion Criteria: * ongoing therapy for another neoplasia * Patients with other hematologic malignancies, * patients deprived of liberty for administrative or judicial reasons * previously treated for myeloma
References
Publications (0)
Data not yet available
No reference posted for this study.